|
|
Blood, 1 November 2007, Vol. 110, No. 9, pp. 3291-3300.
Prepublished online as a Blood First Edition Paper on July 3, 2007; DOI 10.1182/blood-2007-02-075069.
 Previous Article | Next Article 
Submitted February 26, 2007
Accepted June 29, 2007
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
Matthew W Jenner, Paola E Leone, Brian A Walker, Fiona M Ross, David C Johnson, David Gonzalez, Laura Chiecchio, Elisabet Dachs Cabanas, Gian Paolo Dagrada, Mathew Nightingale, Rebecca KM Protheroe, David Stockley, Monica Else, Nicholas J Dickens, Nicholas CP Cross, Faith E Davies, and Gareth J Morgan*
Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom
Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Genetics Laboratory, Salisbury, United Kingdom
* Corresponding author; email: gareth.morgan{at}icr.ac.uk.
We performed FISH for 16q23 abnormalities in 861 patients with newly diagnosed multiple myeloma and identified del(16q) in 19.5%. In 467 cases in which demographic and survival data were available, del(16q) was associated with a worse overall survival. It was an independent prognostic marker and conferred additional adverse survival impact in cases with the known poor risk cytogenetic factors t(4;14) and del(17p). Gene expression profiling and gene mapping using 500K SNP mapping arrays revealed loss of heterozygosity (LOH) involving 3 regions, the whole of 16q, a region centered on 16q12, the location of CYLD, and a region centered on 16q23, the location of WWOX. CYLD is a negative regulator of the NF- B pathway and cases with low expression of CYLD were used to define a "low-CYLD signature". Cases with 16q LOH or t(14;16) had significantly reduced WWOX expression. WWOX, the site of the translocation breakpoint in t(14;16) cases, is a known tumor suppressor gene involved in apoptosis and we were able to generate a "low-WWOX signature" defined by WWOX expression. These two genes and their corresponding signatures provide an important insight in to the potential mechanisms by which 16q LOH confers poor prognosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al.
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
J. Clin. Oncol.,
September 20, 2009;
27(27):
4585 - 4590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L.R. Brito, B. Walker, M. Jenner, N. J. Dickens, N. J.M. Brown, F. M. Ross, A. Avramidou, J. A.E. Irving, D. Gonzalez, F. E. Davies, et al.
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Haematologica,
January 1, 2009;
94(1):
78 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Maciejewski and G. J. Mufti
Whole genome scanning as a cytogenetic tool in hematologic malignancies
Blood,
August 15, 2008;
112(4):
965 - 974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Xu, J. R. Houck, W. Fan, P. Wang, Y. Chen, M. Upton, N. D. Futran, S. M. Schwartz, L. P. Zhao, C. Chen, et al.
Simultaneous Isolation of DNA and RNA from the Same Cell Population Obtained by Laser Capture Microdissection for Genome and Transcriptome Profiling
J. Mol. Diagn.,
March 1, 2008;
10(2):
129 - 134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
